Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in Moderate to Severe Psoriasis
NCT02201524Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of abrocitinib in plaque psoriasis, sponsored by Pfizer. Started Nov 2014; status: terminated.
02
Drugs
abrocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02201524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201524.